Human Embryonic Stem Cells in the Treatment of Patients With Duchenne Muscular Dystrophy: A Case Series

Geeta Shroff

Abstract


Duchenne muscular dystrophy (DMD), an X-linked disorder, occurs due to mutation, deletion or duplication of the DMD gene which encodes the protein dystropin. It is estimated to affect 1 in 3,300 boys. The disease progression leads to muscles necrosis. In cases discussed in this article, five patients with DMD were treated with human embryonic stem cells (hESCs). All patients showed stability and mild improvement clinically like the ability to walk, stand, and sit, improved breathing capacity, increased body weight, improved hand functions and improved muscle strength. A remarkable reduction occurred in the creatine phosphokinase (CPK) levels of all the five patients without further deterioration. In conclusion, hESCs might become an effective therapeutic option for DMD in the future. More clinical data are needed to gather evidences supporting the use of hESC in the treatment of DMD.




J Neurol Res. 2015;5(1-2):186-191
doi: http://dx.doi.org/10.14740/jnr326w


Keywords


Human embryonic stem cell; hESC therapy; Duchenne muscular dystrophy; Genetic disorder

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Neurology Research, bimonthly, ISSN 1923-2845 (print), 1923-2853 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.neurores.org   editorial contact: editor@neurores.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.